Skip to content

Tracking Technologies for the Analysis of Mobility in Alzheimer's Disease

The Use of Advanced Tracking Technologies for the Analysis of Mobility in Alzheimer's Disease and Related Cognitive Disorders

Status
UNKNOWN
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00743418
Acronym
SenTra
Enrollment
300
Registered
2008-08-28
Start date
2007-06-30
Completion date
Unknown
Last updated
2008-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dementia

Brief summary

The research is aimed at exploring the application of novel tracking technique for the study of spatial activity among dementia patients and its implication on their families. The study sample will be composed of three groups of volunteers, each including100 participants aged over 60 years. The first group will include MCI (Mild Cognitive Impairment) patients. The second group will include patients that suffer from mild dementia. The third group will include age matched healthy participants. The tracking equipment will be a GPS apparatus of 450 gms that will be carried by the participants for 24 hours along 2-4 weeks. The GPS data will be transferred via the cellular network to operator center at the Hebrew university at Jerusalem, and will be documented in assigned data files. This monitoring procedure will be held every year and along a period of five years. The impact of the patient behavior on the care giver will be studied by means of five interviews along the tracking period.

Interventions

DEVICEGPS modem and RFID

The participant will take the GPS kit with him/her everywhere during the whole day for a period of 4 weeks. The GPS tracking kit consists of a GPS receiver with a GSM modem, an RF transmitter contained in a wrist-watch and a monitoring unit located in the home that enables researchers to know whenever the tracked person leaves home. The waterproof RF transmitter will allow researchers to know whether or not research subjects leave home with the GPS device and if they are carrying the device or not at a given moment.

Sponsors

Tel-Aviv Sourasky Medical Center
Lead SponsorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patients with MCI, Alzheimer's disease, or mixed type dementia; OR * Healthy control subjects who meet the following criteria: * Mini Mental State (MMSE) of at least 21 * Age 60 years or older * Patients with history of stroke which is not followed by cognitive decline may be included * Fluent language skills

Exclusion criteria

* Other dementias (e.g. vascular, frontotemporal, metabolic etc); * Other major psychiatric disorders (e.g. major depression, schizophrenia); * Substance abuse; * MMSE 20 or less; * Severe motor disturbances; * Sensory deficits potentially affecting mobility; OR * Severe physical disorders (e.g. cancer, major operation)

Design outcomes

Primary

MeasureTime frame
Evaluation tools include: Geriatric Depression Scale, functional health questionnaire (SF-36), Emotional well-being questionnaire (Positive and Negative Affect Schedule; PANAS), single Life Satisfaction question and the Zarit Burden InterviewBefore and after interventions

Countries

Israel

Contacts

Primary ContactJeremia Heinik, MD
jeremiah@tasmc.health.gov.il972-3-6974817

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026